The FDA decision on Gilead Sciences Inc.’s (GILD) proposed HIV treatment Lenacapavir is due on December 27, 2022.Lenacapavir, administered every 6 months as a subcutaneous injection, is being developed for the treatment of HIV-1 infection in heavily treatment-experienced patients with multi-drug resistance in combination with other antiretroviral drugs.This is the company’s second attempt to get approval for Lenacapavir.The FDA had declined to approve Lenacapavir in March of this year, citing Chemistry Manufacturing and Controls (CMC) issues relating to the compatibility of Lenacapavir with the proposed container vial.If approved, Lenacapavir could be the only HIV-1 treatment option administered every six months.GILD closed Friday’s trading at $86.26, up 0.98%.